Anti-androgen therapy for triple-negative breast cancer may benefit lower-androgen tumors

Even triple negative breast cancers expressing very low levels of androgen receptor may benefit from anti-androgen therapy, researchers report. "This line of work is starting to change our thinking about who and when -- the timing and patient selection for anti-androgen receptor therapy in triple-negative breast cancer," says the study's first author.

Read the whole article on Science Daily

More from Science Daily